Key result
CABG 1-2 days after clopidogrel cessation is linked to ~152% higher transfusion odds versus ≥5 days.
Why the study?
Guidelines recommend stopping clopidogrel at least 5 days before CABG to reduce bleeding risk, but this delay may increase cardiovascular risk, prompting evaluation of discontinuation timing on outcomes.
Does clopidogrel discontinuation 1-4 days prior to CABG increase bleeding and transfusion requirements compared to ≥ 5 days in patients treated with clopidogrel?
Cohort (n=472)
No
Does clopidogrel discontinuation 1-4 days prior to CABG increase bleeding and transfusion requirements compared to ≥ 5 days in patients treated with clopidogrel?
Effect estimate: OR 2.52 (95% CI 1.32-4.83)
A waiting period of at least 5 days between clopidogrel cessation and CABG is associated with lower transfusion requirements, supporting current guideline recommendations.
CABG <5 days after clopidogrel raised transfusion odds without increasing major bleeding; leaves open optimal discontinuation timing pending RCTs.
Objectives Current guidelines advise stopping clopidogrel at least 5 days prior to coronary artery bypass grafting (CABG) in patients with acute coronary syndrome to lower bleeding risk. However, this delay may increase the risk of cardiovascular events. This study evaluated the impact of clopidogrel discontinuation timing on bleeding and postoperative outcomes. Methods This retrospective single‐center study analyzed data from 472 patients treated with clopidogrel who underwent CABG. Patients were grouped based on the duration between clopidogrel cessation and surgery: 1–2 days ( n = 42), 3–4 days ( n = 89), and ≥ 5 days ( n = 341). Outcomes included bleeding complications and transfusion requirements. Results No significant difference was found in clinically substantial bleeding (defined as chest tube drainage > 800 mL within 12 h postsurgery) among the groups ( p = 0.45). However, earlier surgery was associated with greater transfusion requirements. Patients operated on within 1–2 days had 2.52 times higher odds of requiring blood product transfusion (95% CI: 1.32–4.83), and those at 3–4 days had 1.69 times higher odds (95% CI: 1.05–2.71), compared to those with ≥ 5 days. Conclusions In this single‐center cohort, a waiting period of at least 5 days between clopidogrel cessation and CABG was associated with lower transfusion requirements, without a clear increase in early clinically substantial bleeding, thereby supporting current guideline recommendations for stable patients.
No takes yet. Share an insight, caveat, or question.
Friedman et al. (2026) conducted a cohort in Patients treated with clopidogrel undergoing CABG (n=472). Clopidogrel cessation 1-2 days prior to surgery vs. Clopidogrel cessation ≥ 5 days prior to surgery was evaluated on Blood product transfusion requirement (OR 2.52, 95% CI 1.32-4.83). Performing CABG 1-2 days after clopidogrel cessation was associated with higher odds of blood product transfusion compared to waiting ≥5 days (OR 2.52; 95% CI 1.32-4.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: